Difference between revisions of "Melphalan (Alkeran)"

Revision as of 16:43, 1 March 2019

General information

Class/mechanism: Nitrogen mustard, alkylator. Melphalan is a bischloroethylamine alkylating agent that crosslinks DNA by binding at the N7 position of guanine, with activity against resting and proliferating cells.^[1]^[2]
Route: IV, PO
Extravasation: irritant or neutral, depending on reference

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.^[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

1/17/1964: Initial FDA approval^[5]

Also known as

Generic names: L-PAM, L-Sacrolysin, L-Sarcolysin, MPL, phenylalanine mustard
Brand names: Alkeran, Alkerana, Levofolan, Melfalan

References

[insert-1] 1.0 ^1.1 Melphalan (Alkeran) package insert

[2] Melphalan (Alkeran) package insert (locally hosted backup)

[3] Melphalan (Alkeran) patient drug information (Chemocare)

[4] Melphalan (Alkeran) patient drug information (UpToDate)

[5] Melphalan (Alkeran) FDA approval history

[1]

[2]

[3]

[4]

[5]

@@ Line 10: / Line 10: @@
 *[[CNS lymphoma]]
 *[[Diffuse large B-cell lymphoma]]
-*[[Ewing's sarcoma]]
+*[[Ewing sarcoma]]
 *[[Follicular lymphoma]]
 *[[HIV-associated lymphoma]]